85. Idiopathic interstitial pneumonia Clinical trials / Disease details
Clinical trials : 598 / Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-002709-23-NL (EUCTR) | 16/02/2021 | 06/08/2020 | A study to assess the efficacy, safety and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis | A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IPF) (INTEGRIS-IPF) | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: PLN-74809 Product Code: PLN-74809 INN or Proposed INN: Not Available Other descriptive name: PLN-74809-020 | Pliant Therapeutics Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 112 | Phase 2 | France;United States;Canada;Belgium;Australia;Germany;Netherlands;United Kingdom;New Zealand;Italy;Korea, Republic of | ||
| 2 | EUCTR2019-002709-23-IT (EUCTR) | 29/12/2020 | 24/05/2021 | A study to assess the efficacy, safety and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis | A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN 74809 in participants with idiopathic pulmonary fibrosis (IPF) (INTEGRIS-IPF) - INTEGRIS-IPF | idiopathic pulmonary fibrosis MedDRA version: 20.0;Level: SOC;Classification code 10038738;Term: Respiratory, thoracic and mediastinal disorders;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: PLN-74809 Product Code: [PLN-74809] Other descriptive name: PLN-74809-000 | Pliant Therapeutics Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 84 | Phase 2 | France;United States;Canada;Belgium;Australia;Netherlands;Germany;United Kingdom;New Zealand;Italy | ||
| 3 | EUCTR2019-002709-23-DE (EUCTR) | 18/12/2020 | 31/01/2020 | A study to assess the efficacy, safety and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis | A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 inparticipants with idiopathic pulmonary fibrosis (IPF) (INTEGRIS-IPF) | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: PLN-74809 Product Code: PLN-74809 INN or Proposed INN: Not Available Other descriptive name: PLN-74809-020 | Pliant Therapeutics Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 112 | Phase 2 | United States;France;Canada;Belgium;Australia;Netherlands;Germany;United Kingdom;New Zealand;Italy;Korea, Republic of | ||
| 4 | EUCTR2019-002709-23-GB (EUCTR) | 06/11/2020 | 24/01/2020 | A study to assess the efficacy, safety and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis | A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IPF) (INTEGRIS-IPF) | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: PLN-74809 Product Code: PLN-74809 INN or Proposed INN: Not Available Other descriptive name: PLN-74809-000 Product Name: PLN-74809 Product Code: PLN-74809 INN or Proposed INN: Not available Other descriptive name: PLN-74809-000 Product Name: PLN-74809 Product Code: PLN-74809 INN or Proposed INN: Not Available Other descriptive name: PLN-74809-000 | Pliant Therapeutics Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | Phase 2 | United States;France;Canada;Belgium;Australia;Netherlands;Germany;New Zealand;Italy;United Kingdom | ||
| 5 | NCT04396756 (ClinicalTrials.gov) | March 3, 2020 | 6/5/2020 | Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Dose-ranging, Placebo Controlled Phase 2a Evaluation of the Safety, Tolerability and Pharmacokinetics of PLN-74809 in Participants With Idiopathic Pulmonary Fibrosis (INTEGRIS-IPF) | Idiopathic Pulmonary Fibrosis | Drug: PLN-74809;Drug: Placebo | Pliant Therapeutics, Inc. | NULL | Recruiting | 40 Years | N/A | All | 84 | Phase 2 | United States;Australia;Belgium;Canada;Italy;Netherlands;New Zealand |
| 6 | NCT04072315 (ClinicalTrials.gov) | September 9, 2019 | 23/8/2019 | Phase 2a Evaluation of PLN-74809 on avß6 Receptor Occupancy Using PET Imaging in Participants With IPF/ | A Phase 2a Evaluation of PLN-74809 on avß6 Receptor Occupancy Using PET Imaging in Participants With IPF | Idiopathic Pulmonary Fibrosis | Drug: PLN-74809;Radiation: Knottin tracer | Pliant Therapeutics, Inc. | Stanford University | Recruiting | 40 Years | N/A | All | 12 | Phase 2 | United States |